Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
158.14
-0.99 (-0.62%)
At close: Apr 23, 2025, 4:00 PM
158.00
-0.14 (-0.09%)
Pre-market: Apr 24, 2025, 7:32 AM EDT
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 202, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 27.73% from the current stock price of 158.14.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Ascendis Pharma stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 7 | 7 |
Buy | 6 | 6 | 6 | 6 | 6 | 7 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 13 | 14 | 14 | 14 | 15 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Initiates $205 | Buy | Initiates | $205 | +29.63% | Apr 16, 2025 |
JP Morgan | JP Morgan | Buy Maintains $168 → $200 | Buy | Maintains | $168 → $200 | +26.47% | Mar 18, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $170 → $200 | Buy | Maintains | $170 → $200 | +26.47% | Feb 25, 2025 |
Evercore ISI Group | Evercore ISI Group | Buy Maintains $220 → $260 | Buy | Maintains | $220 → $260 | +64.41% | Feb 18, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $200 → $225 | Strong Buy | Maintains | $200 → $225 | +42.28% | Feb 13, 2025 |
Financial Forecast
Revenue This Year
587.04M
from 363.64M
Increased by 61.43%
Revenue Next Year
1.02B
from 587.04M
Increased by 73.07%
EPS This Year
-3.66
from -6.53
EPS Next Year
1.13
from -3.66
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 800.1M | 1.6B | 2.6B | ||
Avg | 587.0M | 1.0B | 1.6B | ||
Low | 473.5M | 703.8M | 1.1B |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 120.0% | 179.4% | 153.5% | ||
Avg | 61.4% | 73.1% | 53.1% | ||
Low | 30.2% | 19.9% | 8.6% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.34 | 7.03 | 11.26 | ||
Avg | -3.66 | 1.13 | 5.64 | ||
Low | -6.17 | -2.53 | 2.38 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 891.9% | ||
Avg | - | - | 396.9% | ||
Low | - | - | 109.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.